NCT01252849
Completed
N/A
A Prospective, Randomized, Controlled Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications, Implanted With One, Two, or Three Trabecular Micro-Bypass Stents
ConditionsPrimary Open Angle Glaucoma (POAG)
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Primary Open Angle Glaucoma (POAG)
- Sponsor
- Glaukos Corporation
- Enrollment
- 119
- Locations
- 1
- Primary Endpoint
- Mean diurnal IOP reduction of greater than or equal to 20% at month 12 vs. baseline
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of the iStent medical device that is implanted into the eye and designed to reduce eye pressure in patients with your condition.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosed with primary open-angle glaucoma (POAG)
- •Subject on two topical hypotensive medications
Exclusion Criteria
- •Traumatic, uveitic, neovascular, or angle closure glaucoma
- •Fellow eye already enrolled
Outcomes
Primary Outcomes
Mean diurnal IOP reduction of greater than or equal to 20% at month 12 vs. baseline
Time Frame: 12 Months
Secondary Outcomes
- Mean diurnal IOP <18 mmHg at month 12(12 months)
Study Sites (1)
Loading locations...
Similar Trials
Completed
N/A
Safety and Effectiveness of an Auricular SprayExcessive Ear WaxNCT06085443YSLab99
Terminated
Phase 2
Study of Occipital Nerve Stimulation for Drug Refractory MigraineMigraineNCT00747812Boston Scientific Corporation11
Active, Not Recruiting
N/A
HF-TRACK: A UK RCT of an Passive Heart Failure Monitoring and Tracking DeviceHeart FailureNCT06334822Heartfelt Technologies186
Not Yet Recruiting
N/A
Study on the Efficacy and Safety of a Device for Post-op Recovery in Pediatric Adenectomy/Adenotonsillectomy.Adenoidal DisorderTonsillitisOtorhinolaryngologic DiseasesNasal DiseaseNCT06478433Pharmaluce srl90
Completed
N/A
A Study Evaluating the Efficiency and Safety for the VGuard Device in Alzheimer's Disease.Alzheimer Disease (AD)NCT06620640Neuromedical Sp. z o.o.105